

Rec'd PCT/PTO 24 JUN 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



10/540763



(43) International Publication Date  
15 July 2004 (15.07.2004)

PCT

(10) International Publication Number  
WO 2004/058239 A1

- (51) International Patent Classification<sup>7</sup>: A61K 31/185, 38/00, A61P 25/28
- (74) Agent: OGILVY RENAULT; Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).
- (21) International Application Number: PCT/CA2003/002021
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 24 December 2003 (24.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/436,379 24 December 2002 (24.12.2002) US  
60/482,214 23 June 2003 (23.06.2003) US
- (84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): NEUROCHEM (INTERNATIONAL) LIMITED [CH/CH]; Neuhausstrasse 5, CH-6318 Walchwil (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): GERVAIS, Francine [CA/CA]; 1003 Bellevue, Ile Bizard, Québec H9C 2X5 (CA). BELLINI, Francesco [CA/CA]; 307 Portland Avenue, Town of Mount Royal, Québec H3R 1V4 (CA).
- Published:  
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES

(57) Abstract: The method is used for preventing or treating an amyloid- $\beta$  related disease in a subject. The method comprises administering to a subject in need thereof an effective amount of a first agent that prevents or treats amyloid- $\beta$  related disease, and a second agent that is (i) a peptide or peptidomimetic that modulates amyloid- $\beta$  fibril formulation or induces a prophylactic or therapeutic immune response against amyloid- $\beta$  fibril formulation, or (ii) an immune system modulator that prevents or inhibits amyloid- $\beta$  fibril formulation.

WO 2004/058239 A1